Skip to main content

Table 5 Patient distribution in relation to longitudinal 6–months interval change in FVC % of predicted (ΔFVC) and TLCO % of predicted (ΔTLCO)

From: A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study

ΔFVC

0–6 months

6–12 months

12–18 months

18–24 months

significant improvement (∆FVC >10%)

marginal improvement (10% ≥ ∆FVC>5%)

stabilization (+5% ≥ ∆FVC>-5%)

marginal decline (−5% ≥ ∆FVC>-10%)

significant decline (∆FVC ≤ -10%)

n

14 (5.6%)

35 (14%)

152 (60.8%)

31 (12.4%)

18 (7.2%)

250

7 (3.1%)

25 (11.2%)

152 (68.2%)

28 (12.6%)

11 (4.9%)

223

4 (2.9%)

9 (6.6%)

89 (65%)

31 (22.6%)

4 (2.9%)

137

0 (0%)

2 (3.6%)

36 (65.5%)

16 (29.1%)

1 (1.8%)

55

∆TLCO

0–6 months

6–12 months

12–18 months

18–24 months

significant improvement (∆TLCO >15%)

stabilization (+15% ≥ ∆TLCO>-15%)

significant decline (∆TLCO ≤ -15%)

n

4 (1.7%)

210 (87.1%)

27 (11.2%)

241

4 (1.8%)

197 (90.8%)

16 (7.4%)

217

8 (5.7%)

119 (85%)

13 (9.3%)

140

1 (1.6%)

55 (87.3%)

7 (11.1%)

63

  1. Abbreviations: FVC forced vital capacity, TLCO transfer factor of the lung for carbon monoxide